Ontak Treatment Can Lead To Color Vision Loss, Company Warns
This article was originally published in The Pink Sheet Daily
Executive Summary
Loss of visual acuity has been reported in some patients treated with the oncologic, according to a new warning added to labeling and a "Dear Doctor" letter.
You may also be interested in...
Merck’s Zolinza Approved For Rare Skin Cancer
The oncologic is first in its class for treatment of cutaneous T-cell lymphoma.
Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says
Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.